Filipa Oliveira

Ms. Filipa Oliveira

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FOFilipa Oliveira
Filipa Oliveira
MCMiguel Castanho
Miguel Castanho
VNVera Neves
Vera Neves
Brain metastases (BM) are a frequent complication in patients with advanced stages of cancer, associated with impairment of the neurological function, quality of life, prognosis, and survival. BM treatment consists of a combination of the available cancer therapies, such as surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapies. Even so, cancer patients with BM are still linked to poor prognosis, with overall survival being reported as 12 months or less. Intercellular communication has a pivotal role in the development of metastases, therefore, it has been extensively studied not only to better understand the metastization process, but also to further develop new therapeutic strategies. Exosomes have emerged as key players in intercellular communication being potential therapeutic targets, drug delivery systems (DDS) or biomarkers. In this Review, we focus on the role of these extracellular vesicles (EVs) in BM formation and their promising application in the development of new BM therapeutic strategies.

16 October 2017 in Nanoscale
Verified
Journal Article
Open access
PDF file
TFTiago N. Figueira
Tiago N. Figueira
FOFilipa Oliveira
Filipa Oliveira
IAInês Almeida
Inês Almeida
ÉMÉrica O. Mello
Érica O. Mello
VGValdirene Gomes
Valdirene Gomes
DGDiana Gaspar
Diana Gaspar
Metastatic breast cancer is a very serious life threatening condition that poses many challenges for the pharmaceutical development of effective chemotherapeutics. As the therapeutics targeted to the localized masses in breast improve, metastatic lesions in the brain slowly increase in their incidence compromising successful treatment outcomes overall. The blood–brain-barrier (BBB) is one important obstacle for the management of breast cancer brain metastases. New therapeutic approaches are in demand for overcoming the BBB's breaching by breast tumor cells. In this work we demonstrate the potential dual role of a natural antimicrobial plant defensin, PvD1: it interferes with the formation of solid tumors in the breast and concomitantly controls adhesion of breast cancer cells to human brain endothelial cells. We have used a combination of techniques that probe PvD1's effect at the single cell level and reveal that this peptide can effectively damage breast tumor cells, leaving healthy breast and brain cells unaffected. Results suggest that PvD1 quickly internalizes in cancer cells but remains located in the membrane of normal cells with no significant damage to its structure and biomechanical properties. These interactions in turn modulate cell adhesiveness between tumor and BBB cells. PvD1 is a potential template for the design of innovative pharmacological approaches for metastatic breast cancer treatment: the manipulation of the biomechanical properties of tumor cells that ultimately prevent their attachment to the BBB.

3 December 2019 in Nanoscale
Verified
Journal Article
Open access
PDF file
JSJulia Skalska
Julia Skalska
FOFilipa Oliveira
Filipa Oliveira
TFTiago N. Figueira
Tiago N. Figueira
ÉMÉrica O. Mello
Érica O. Mello
VGValdirene M. Gomes
Valdirene M. Gomes
DGDiana Gaspar
Diana Gaspar
Plant defensin Pv D 1 attenuates recruitment of CD63 and CD9 to emerging exosomes of breast cancer MCF-7 cells, and binds to mature exosomes, which uncovers the nutraceutical potential of the natural source of Pv D 1 , the bean Phaseolus vulgaris .

22 October 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
FOFilipa Oliveira
Filipa Oliveira
Marco CavacoMarco Cavaco
Marco Cavaco
TFTiago N. Figueira
Tiago N. Figueira
JVJavier Valle
Javier Valle
VNVera Neves
Vera Neves
MCMiguel Castanho
Miguel Castanho
The incidence of metastatic breast cancer (MBC) is increasing and the therapeutic arsenal available to fight it is insufficient. Brain metastases, in particular, represent a major challenge for chemotherapy as the impermeable nature of the blood–brain barrier (BBB) prevents most drugs from targeting cells in the brain. For their ability to transpose biological membranes and transport a broad spectrum of bioactive cargoes, cell‐penetrating peptides (CPPs) have been hailed as ideal candidates to deliver drugs across biological barriers. A more ambitious approach is to have the CPP as a drug itself, capable of both killing cancer cells and interacting with the blood/brain interface, therefore blocking the onset of brain metastases. vCPP2319, a viral protein‐derived CPP, has both properties as it: (a) is selective toward human breast cancer cells (MDA‐MB‐231) and increases cell stiffness compared to breast epithelial cells (MCF 10A) hindering the progression of metastases; and (b) adsorbs at the surface of human brain endothelial cells potentially counteracting metastatic cells from reaching the brain. Overall, the results reveal the selective anticancer activity of the peptide vCPP2319, which is also able to reside at the blood–brain interface, therefore counteracting brain penetration by metastatic cancer cells.